Skip to main content
. 2021 Nov 4;39(51):7429–7440. doi: 10.1016/j.vaccine.2021.10.079

Fig. 4.

Fig. 4

Number of times more likely to develop and die from atypical blood clots (CVST and PVT) in COVID-19 patients (i.e., those with symptomatic infection) than from AZ-vaccine-induced TTS, by age group and sex.